- President and CEO of Cardiff Lexington, Alex Cunningham, to succeed Daniel Thompson as Chairman - LEXINGTON, KY / ACCESS Newswire / December 29, 2025 / Cardiff Lexington Corporation (OTCQB:CDIX) ("Cardiff" or the "Company"), a healthcare holding company with deep leadership and operational expertise in Orthopedics, Spine Care, and Pain Management, today announced that Daniel Thompson will retire from his position as Chairman of the Board of Directors, effective December 31, 2025, after 25 years of dedicat ...

®OneStep's Clinically Validated Mobility Intelligence Technology to Integrate into Zimmer Biomet's mymobility Care Management Platform to Further Enhance Recovery Monitoring WARSAW, Ind., Dec. 16, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, and OneStep, the FDA-listed digital fall prevention and mobility intelligence platform, today announced an exclusive collaboration agreement aimed at delivering the orthopedic industry's most comprehensive se ...

Smith & Nephew (NYSE:SNN) 2025 Capital Markets Day December 11, 2025 09:00 AM ET Company ParticipantsCaitlin Roberts - DirectorRohit Kashyap - President of World BusinessHadi El-Heneidi - Senior Director of Global MarketingDeepak Nath - CEOJohn Rogers - CFOIseult McMahon - Equity Research AssociateScott Schaffner - President of Sports MedicineSteven Hass - Orthopedic SurgeonCathy Dalene - SVP of Global Wound CareMayank Shandil - Global Senior VPMike Ast - Director of Asc StrategyAnil Ranawat - Orthopedic Su ...

LEXINGTON, KY / ACCESS Newswire / December 11, 2025 / Cardiff Lexington Corporation (OTCQB:CDIX), a healthcare holding company with deep leadership and operational expertise in Orthopedics, Spine Care, and Pain Management, today announced that the Company's subsidiary, Nova Ortho and Spine, performed its first procedures at Doctor's Memorial Hospital in Perry, Florida, demonstrating Cardiff Lexington's ongoing commitment to providing best-in-class healthcare to severely underserved and rural patient populat ...

Core Insights - Enovis is positioned as a challenger brand in the orthopedic market, competing against the major players in the industry [1] - The company boasts an innovative portfolio that spans the entire patient continuum, from prevention to recovery, which enhances its market appeal [1] - Enovis has strategically balanced its portfolio with 50% of its revenue coming from the U.S. and 50% from international markets, as well as a split of 50% in products and revenue (P&R) and 50% in reconstruction (Recon) [1] - Within the reconstruction segment, Enovis has a balanced focus on extremities and large implants, each accounting for 50% of that segment [1]

Core Insights - OrthoPediatrics Corp. is focused on advancing pediatric orthopedics and will participate in three upcoming investor conferences [1][2] Group 1: Upcoming Events - The company will participate in the Stifel 2025 Healthcare Conference on November 13, 2025, at 1:20 pm ET in a fireside chat format [1] - OrthoPediatrics will present at the Jeffries Global Healthcare Conference in London on November 18, 2025, at 12:00 pm ET [1] - The company will also engage in a fireside chat at the Piper 37 Annual Healthcare Conference on December 4, 2025, at 9:30 am ET [1] Group 2: Company Overview - Founded in 2006, OrthoPediatrics specializes in pediatric orthopedics and has developed a comprehensive product offering to improve the lives of children with orthopedic conditions [2] - The company markets over 80 products across three major categories: trauma and deformity, scoliosis, and sports medicine/other procedures [2] - OrthoPediatrics has a global sales organization focused exclusively on pediatric orthopedics, distributing products in the United States and over 70 countries worldwide [2]

Core Viewpoint - OrthoPediatrics Corp. is set to release its third quarter 2025 financial results on October 28, 2025, and will host a conference call to discuss these results [1]. Company Overview - OrthoPediatrics Corp. was founded in 2006 and focuses exclusively on pediatric orthopedics, offering a comprehensive range of over 80 products [3]. - The company serves three major categories within the pediatric orthopedic market: trauma and deformity, scoliosis, and sports medicine/other procedures [3]. - OrthoPediatrics distributes its products in the United States and over 70 countries globally, emphasizing its commitment to improving the lives of children with orthopedic conditions [3]. Investor Information - Investors can access a live and archived webcast of the conference call on the company's website, which will be available for replay for at least 90 days [2]. - The conference call is scheduled for October 28, 2025, at 4:30 p.m. ET [1].

Johnson & Johnson says it plans to separate its slower-growing orthopedics business from the rest of the company within 18 to 24 months https://t.co/jwAdzHkoWU ...

Summary of Key Points Core Viewpoint - U.S. stock futures showed slight gains, while several companies reported disappointing financial results leading to significant pre-market trading declines in their shares [1][4]. Company-Specific Summaries - **Nurix Therapeutics Inc (NASDAQ:NRIX)**: - Reported a quarterly loss of $1.03 per share, worse than the expected loss of $0.88 per share - Sales were $7.894 million, missing expectations of $16.736 million - Shares fell 5.8% to $10.24 in pre-market trading [1][2]. - **Venture Global, Inc. (NYSE:VG)**: - Shares dipped 18.4% to $10.27 following a resolution related to an arbitration proceeding concerning the Calcasieu Pass facility [4]. - **Orthopediatrics Corp (NASDAQ:KIDS)**: - Shares fell 15% to $15.25 after the company cut its FY25 revenue guidance [4]. - **Inventiva S.A. (NYSE:IVA)**: - Shares declined 13.6% to $4.78 in pre-market trading [4]. - **USANA Health Sciences Inc (NYSE:USNA)**: - Shares declined 13% to $22.83 after reporting preliminary results for the third quarter, with an adjusted loss of $0.15 per share and sales of $214 million [4]. - **Nanobiotix S.A. (NASDAQ:NBTX)**: - Shares declined 8.1% to $27.48 after a previous gain of 10% [4]. - **Diginex Limited (NASDAQ:DGNX)**: - Shares fell 7.6% to $29.00 in pre-market trading [4]. - **Levi Strauss & Co (NYSE:LEVI)**: - Reported quarterly earnings of $0.34 per share, beating the analyst consensus estimate of $0.31 per share - Quarterly sales were $1.543 billion, exceeding the analyst consensus estimate of $1.501 billion - Shares tumbled 7.1% to $22.81 in pre-market trading [4].

Core Insights - OrthoPediatrics Corp. is expanding its OrthoPediatrics Specialty Bracing (OPSB) division with new clinics and entry into new territories, including California, Ohio, and Colorado [1][6] - The company is slightly ahead of its planned entry into four new target markets for 2025, aiming to provide better bracing and O&P care to children globally [3][4] - The expansion includes Acquihire opportunities with new operations in New York and Ireland, marking the first international market for OPSB [2][6] Company Overview - Founded in 2006, OrthoPediatrics focuses exclusively on pediatric orthopedics, offering over 80 products across trauma and deformity, scoliosis, and sports medicine categories [5] - The company distributes its products in the United States and over 70 countries, emphasizing its commitment to improving the lives of children with orthopedic conditions [5] Market Expansion - The new clinic in California targets the Los Angeles market, providing access to millions of potential pediatric patients [6] - The Dayton, OH clinic is located within Dayton Children's Hospital, enhancing local access to skilled clinicians [6] - The expansion into Ireland complements OrthoPediatrics' existing implant business and opens opportunities for further growth in Europe [6]